Full-Time

Crystal Structure Prediction Scientist

Confirmed live in the last 24 hours

Schrödinger

Schrödinger

501-1,000 employees

Computational platform for biopharmaceutical research

Enterprise Software
Biotechnology
Healthcare

Compensation Overview

$120k - $190kAnnually

Senior

New York, NY, USA

Category
Computational Biology
Biology & Biotech
Required Skills
Python
C/C++
Requirements
  • PhD in computational chemistry, solid state physics, solid state property modeling, or related fields
  • Peer-reviewed publications on crystal structure prediction, solid state property modeling, computational chemistry, and/or materials modeling
  • Proficiency in Python or C++; Python is preferred
  • Experience in developing crystal structure prediction methods is highly desired
Responsibilities
  • Facilitate breakthroughs in computer-aided drug discovery and materials design by delivering novel methods with unprecedented levels of accuracy
  • Work with a team of scientists and engineers to develop novel methods to accurately predict small molecule crystal structures
  • Carefully design computational experiments and collect data to validate the methods and explore applications areas

Schrödinger provides a computational platform that aids in the research efforts of biopharmaceutical companies, academic institutions, and government laboratories around the world. Their platform offers advanced computational tools that help in drug discovery and development across various therapeutic areas. Schrödinger's products work by utilizing sophisticated algorithms and simulations to predict molecular behavior, which assists researchers in identifying potential drug candidates more efficiently. What sets Schrödinger apart from its competitors is its extensive global reach, serving clients in over 70 countries, and its dual focus on both software licensing and collaborative drug discovery programs. The company's goal is to advance scientific research and innovation by enhancing its computational platform and fostering partnerships that lead to successful drug development.

Company Stage

Grant

Total Funding

$362.7M

Headquarters

New York City, New York

Founded

1990

Growth & Insights
Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Simplify Jobs

Simplify's Take

What believers are saying

  • Schrödinger's rapid identification of development candidates, such as SGR-1505, significantly accelerates the drug discovery process, offering a competitive advantage.
  • Recent investments from firms like Duality Advisers LP and Moody Aldrich Partners LLC indicate strong market confidence in Schrödinger's growth potential.
  • The company's expansion into new space in New York reflects its growth trajectory and commitment to scaling its operations.

What critics are saying

  • The high costs associated with expanding physical space and investing in new technologies could strain financial resources if not managed carefully.
  • The competitive nature of the drug discovery and computational chemistry sectors means Schrödinger must continuously innovate to maintain its edge.

What makes Schrödinger unique

  • Schrödinger's unique integration of physics-based computational methods with machine learning sets it apart in the drug discovery landscape.
  • The company's ability to triage billions of compounds and identify development candidates in a fraction of the typical time showcases its technological edge.
  • Schrödinger's commitment to ESG initiatives, as highlighted in their annual Corporate Sustainability report, adds a layer of corporate responsibility that differentiates it from many competitors.

Help us improve and share your feedback! Did you find this helpful?